Clinical Trial Update: LAM Pilot Study With Imatinib Mesylate [Phase 1, Phase 2]

View source ↗

Summary

A pilot study investigating imatinib mesylate for lymphangioleiomyomatosis has completed Phase 1 and Phase 2 with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphangioleiomyomatosis

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Lymphangioleiomyomatosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-03-26